William Blair Lifts Earnings Estimates for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at William Blair boosted their Q2 2025 earnings per share estimates for Legend Biotech in a report released on Tuesday, May 13th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.22) per share for the quarter, up from their prior forecast of ($0.33). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.44 EPS.

Several other research analysts also recently commented on LEGN. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Legend Biotech in a research report on Wednesday, April 16th. Morgan Stanley dropped their target price on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $55.00 price target on shares of Legend Biotech in a research report on Wednesday. Truist Financial cut their price objective on shares of Legend Biotech from $88.00 to $71.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $84.00 target price on shares of Legend Biotech in a research report on Tuesday, April 22nd. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Legend Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $74.73.

Legend Biotech Trading Down 0.4%

Legend Biotech stock opened at $27.69 on Friday. Legend Biotech has a 52 week low of $27.43 and a 52 week high of $60.87. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98. The firm has a market capitalization of $5.09 billion, a PE ratio of -29.15 and a beta of 0.20. The business’s 50-day simple moving average is $33.66 and its 200-day simple moving average is $35.97.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.33. The firm had revenue of $195.05 million for the quarter, compared to the consensus estimate of $190.83 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LEGN. Exane Asset Management bought a new position in shares of Legend Biotech in the fourth quarter valued at approximately $2,284,000. Matthews International Capital Management LLC increased its holdings in Legend Biotech by 14.9% during the 4th quarter. Matthews International Capital Management LLC now owns 1,185,516 shares of the company’s stock valued at $38,577,000 after purchasing an additional 153,665 shares in the last quarter. Asset Management One Co. Ltd. raised its position in Legend Biotech by 26.1% in the 4th quarter. Asset Management One Co. Ltd. now owns 11,085 shares of the company’s stock valued at $360,000 after purchasing an additional 2,297 shares during the last quarter. New York State Common Retirement Fund raised its position in Legend Biotech by 196.1% in the 4th quarter. New York State Common Retirement Fund now owns 59,276 shares of the company’s stock valued at $1,929,000 after purchasing an additional 39,256 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in Legend Biotech by 1,513.3% in the fourth quarter. Blue Trust Inc. now owns 5,840 shares of the company’s stock worth $190,000 after purchasing an additional 5,478 shares in the last quarter. 70.89% of the stock is currently owned by institutional investors and hedge funds.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).